Contribute Try STAT+ Today

Hello, everyone, and nice to see you again after an extended weekend break, which included a holiday on this side of the pond. Our time was well spent but, nonetheless, the usual routine has resumed. What can you do? The world, such as it is, keeps spinning, at least for now. So time to get cracking. We are reaching out to our list of secret contacts, measuring the to-do list, and firing up the coffee kettle — our choice today is wild mountain blueberry. Please feel free to join us. Meanwhile, here are a few tidbits to get you going. Hope you have a productive day and conquer the world. And as always, do keep in touch. …

A large majority of Americans support allowing the U.S. government to negotiate for Medicare drugs and this support holds steady even after the public is provided the arguments being presented by parties on both sides of the legislative debate, Kaiser Health News writes, citing a Kaiser Family Foundation poll. In all, 83% support negotiations. Along party lines, 95% of Democrats, 82% of independents, and 71% of Republicans back negotiations. Most adults do not believe high drug prices are needed for drug makers to invest in new research, instead agreeing that “even if U.S. prices were lower, drug companies would still make enough money to invest in the research needed to develop new drugs.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment